Your search Palbociclib did not match any manufacturers. You may consider to:
Check the spelling
Use less keywords
Use different keywords
Welcome back!
Palbociclib (Ibrane(R), Pfizer), a selective CDK4 and CDK6 inhibitor, received accelerated approval from FDA in 2015 for women with estrogen receptor-positive and HER2-negative breast cancer in combination with letrozole.
Check the spelling
Use less keywords
Use different keywords